Where, after the submission of the amended briefing package, the health technology developer submits updates related to the amended development plan for the relevant medicinal product, the JSC Subgroup shall ensure that those updates are considered in the outcome document, provided that it receives them no later than 10 days before the meeting referred to in Article 18(7) of Regulation (EU) 2021/2282.
In addition to the rules set out in paragraph 1, where the joint scientific consultation on medicinal products is carried out in parallel with the scientific advice, the following shall apply:
the health technology developer shall submit the amended development plan referred to in paragraph 1 at the same time to the HTA secretariat and the European Medicines Agency;
the Coordination Group shall approve the joint scientific consultation outcome document and the Committee for Medicinal Products for Human Use of the European Medicines Agency shall adopt the advice letter to the health technology developer within the deadline set in the timetable referred to in Article 4(1);
the HTA secretariat and the European Medicines Agency shall exchange with each other the outcome document approved by the Coordination Group and the advice letter adopted by the Committee for Medicinal Products for Human Use on the same day as sending them to the health technology developer.